Literature DB >> 33041206

Peri-operative, long-term, and quality of life outcomes after pancreaticoduodenectomy in the elderly: greater justification for periampullary cancer compared to pancreatic head cancer.

Amir Parray1, Manish S Bhandare2, Saneya Pandrowala1, Vikram A Chaudhari1, Shailesh V Shrikhande1.   

Abstract

BACKGROUND: Pancreaticoduodenectomy (PD) is more challenging in the elderly.
METHODS: Data of patients undergoing PD above 70 years of age was analysed to study short and long-term outcomes along with the quality of life parameters (QOL).
RESULTS: Out of 1271 PDs performed, 94 (7%) patients were 70 years or more. American Society of Anaesthesiology (ASA) scores were higher in comparison to patients below 70 years (ASA 1;20% vs. 54% and ASA 2&3;80% vs. 46%, p < 0.001). The postoperative 90-day mortality rate of 5.3% and morbidity (Clavein Grade III and IV of 27%) was higher but non-significant compared to 3.9% (p = 0.50) and 20% (p = 0.11) in patients less than 70 years. The median survival of 40 months was significantly better for periampullary carcinoma when compared to 15 months in pancreatic ductal adenocarcinoma (PDAC) (p < 0.0001). Patients, less than 70 years had significantly better 3-year survival; 64% vs 43% with periampullary etiology (p < 0.01) and 29% vs 0% with PDAC (p < 0.0001). QLQ-PAN 26 questionnaire responses were suggestive of good long term QOL in these patients.
CONCLUSION: Although PD is safe and feasible in the elderly population with good long-term QOL, postoperative morbidity and mortality can be slightly higher and long-term survival significantly lower.
Copyright © 2020 International Hepato-Pancreato-Biliary Association Inc. Published by Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2020        PMID: 33041206     DOI: 10.1016/j.hpb.2020.09.016

Source DB:  PubMed          Journal:  HPB (Oxford)        ISSN: 1365-182X            Impact factor:   3.647


  1 in total

1.  Prognostic Effect of Age in Resected Pancreatic Cancer Patients: A Propensity Score Matching Analysis.

Authors:  Yaolin Xu; Yueming Zhang; Siyang Han; Dayong Jin; Xuefeng Xu; Tiantao Kuang; Wenchuan Wu; Dansong Wang; Wenhui Lou
Journal:  Front Oncol       Date:  2022-03-31       Impact factor: 6.244

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.